Biogen Stock Quote Analysis and Market Trends

Biogen's stock has been on a rollercoaster ride, with its price fluctuating significantly over the years. One of the key factors influencing its stock performance is its pipeline of innovative treatments.

Biogen's pipeline includes several promising therapies for neurological disorders, such as multiple sclerosis and Parkinson's disease. These treatments have the potential to revolutionize the way these conditions are managed.

Biogen's stock price has been impacted by the success of its multiple sclerosis treatment, Tecfidera. Since its approval in 2013, Tecfidera has become a top-selling MS medication, generating billions of dollars in revenue for the company.

The biotech industry is highly competitive, and Biogen faces stiff competition from other players in the market.

Explore further: Meme Stock Price

Biogen's financial performance in 2023 was a mixed bag. The company's revenue decreased by 3.32% to $9.84 billion compared to the previous year's $10.17 billion.

Earnings took a bigger hit, decreasing by 61.89% to $1.16 billion. This significant drop in earnings is a concern for investors.

Biogen's stock performance is also worth looking at. Over the past 7 days, the stock returned 5.8%, outpacing the US Biotechs industry's 4.2% return.

However, over the past year, the stock underperformed the US Biotechs industry, returning -39.9% compared to the industry's -4.3% return. The US Market actually did well, returning 22.7% over the same period.

Here's a summary of Biogen's stock performance compared to the US Biotechs industry and the US Market:

As we dive into the world of Biogen stock, let's take a closer look at some key statistics that can give us a better understanding of the company's performance.

Revenue(TTM) stands at $9,607.5 million, indicating a significant revenue stream for the company.

The EPS(TTM) is a respectable $11.07, suggesting that the company is generating strong earnings per share.

With a beta of -0.03, Biogen's stock is considered to be relatively stable and less volatile compared to the market average.

The 3-Year Sharpe Ratio of -0.49 indicates that the company's returns have been below the market average over the past three years.

The 3-Year Sortino Ratio of -0.81 further emphasizes this point, highlighting the company's underperformance in terms of risk-adjusted returns.

Volatility stands at 17.66%, indicating a moderate level of risk associated with investing in Biogen stock.

The 14-Day RSI (Relative Strength Index) of 50.12 suggests that the stock is currently trading at a neutral level, neither overbought nor oversold.

The 14-Day ATR (Average True Range) of $3.697271 indicates the average daily price fluctuation of the stock over the past two weeks.

The 20-Day SMA (Simple Moving Average) of $147.545 provides a benchmark for the stock's short-term price movement.

The 12-1 Month Momentum of -38.2% indicates a significant decline in the stock's price over the past year.

The 52-Week Range of $139.71 - $251.99 highlights the stock's price volatility over the past year.

The Shares Outstanding of 145.72 million indicates the total number of shares currently available for trading.

On a similar theme: Compared to Growth Stocks Value Stocks' Price-earnings Ratio Is Typically

Biogen has made significant strides in the treatment of Alzheimer's disease with the approval of LEQEMBI, an IV maintenance dosing treatment for early Alzheimer's disease. This marks a major breakthrough in the field.

Biogen's ALS drug, Qalsody, has been directed to be covered by private Medicare plans, a significant development for patients suffering from amyotrophic lateral sclerosis. This decision aims to ensure that patients have access to necessary treatments.

Biogen is also making progress in the treatment of systemic lupus erythematosus with its drug dapirolizumab pegol, which has shown positive results in the Phase 3 PHOENYCS GO study. This study indicates potential for the drug to advance the treatment of the condition.

The US FDA has approved monthly maintenance dosing for Eisai's Alzheimer's drug, Leqembi. This new dosing schedule can make it easier for patients and their care partners to continue treatment.

Leqembi is an Alzheimer's drug developed by Eisai and partner Biogen. The FDA has given its approval for monthly maintenance dosing of the drug, which is a significant development for those affected by the disease.

Monthly maintenance dosing allows patients to receive treatment once every four weeks, which can be a more manageable schedule for many. Alzheimer's disease progression does not stop after plaque clearance, so ongoing treatment is crucial.

The US FDA has approved monthly maintenance dosing for Eisai's Alzheimer's drug, Leqembi.

At the J.P. Morgan 43rd Annual Healthcare Conference, Biogen Inc. (BIIB) discussed their Alzheimer's disease drug, Leqembi.

Leqembi is the only FDA-approved anti-amyloid therapy that potentially could offer the convenience of a subcutaneous injection with at-home administration option.

Biogen's Alzheimer's disease drug, Leqembi, is expected to see a "linear trend" in growth in the United States in the near term, according to a company executive.

Biogen's keenly watched Alzheimer's disease drug, Leqembi, is expected to see steady growth in the near term, as mentioned by a company executive at a healthcare conference.

Biogen Inc. (BIIB) presented detailed results from the Phase 3 PHOENYCS GO study evaluating dapirolizumab pegol (DZP) for systemic lupus erythematosus, in collaboration with UCB SA.

The Centers for Medicare & Medicaid Services has directed private insurers providing Medicare Advantage plans to cover Biogen's amyotrophic lateral sclerosis drug, Qalsody.

For your interest: What Are Value Stocks vs Growth Stocks

Biogen proposes to buy the remaining stake in Sage Therapeutics for $442 million.

The deal involves Biogen buying all outstanding shares of Sage that it doesn't already own for $7.22 per share.

This move sent Sage's stock up 34% in extended trade.

Biogen's offer is for $7.22 per share, a figure that's been widely reported.